PCVX Stock Summary and Trading Ideas (Vaxcyte | NASDAQ:PCVX)

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Vaxcyte trades on the NASDAQ stock market under the symbol PCVX.

As of December 8, 2025, PCVX stock price declined to $46.18 with 884,264 million shares trading.

PCVX has a beta of 3.18, meaning it tends to be more sensitive to market movements. PCVX has a correlation of 0.36 to the broad based SPY ETF.

PCVX has a market cap of $6.05 billion. This is considered a Mid Cap stock.

In the last 3 years, PCVX traded as high as $121.06 and as low as $27.66.

The top ETF exchange traded funds that PCVX belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.

PCVX has underperformed the market in the last year with a price return of -48.7% while the SPY ETF gained +13.9%. However, in the short term, PCVX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +39.9% vs +5.9% return in SPY. But in the last 2 weeks, PCVX shares have been beat by the market, returning -3.3% compared to an SPY return of +3.7%.

PCVX support price is $44.73 and resistance is $48.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCVX shares will trade within this expected range on the day.